Literature DB >> 1814975

Dual serotoninergic projections to forebrain in the rat: morphologically distinct 5-HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives.

L A Mamounas1, C A Mullen, E O'Hearn, M E Molliver.   

Abstract

The cerebral cortex of the rat and other mammals is innervated by two morphologically distinct classes of serotoninergic (5-HT) axon terminals: fine axons with minute varicosities and beaded axons characterized by large, spherical varicosities. Fine and beaded 5-HT axons exhibit different regional and laminar distributions in forebrain and arise from separate brainstem nuclei, the dorsal and median raphe nuclei, respectively. The present neuroanatomic study, based on immunocytochemical methods to visualize 5-HT axons, demonstrates that the two axon types differ markedly in their vulnerability to the neurotoxic amphetamine derivatives, methylenedioxyamphetamine (MDA), and p-chloroamphetamine (PCA). While both drugs cause extensive degeneration of fine 5-HT axons throughout forebrain, beaded 5-HT axons are consistently spared. Fine 5-HT axons, which richly innervate most regions of dorsal forebrain in control rats, are rarely seen 2 weeks after treatment with MDA or PCA; this loss of fine axons reflects a marked denervation that persists for months after drug administration. The serotoninergic axon terminals remaining after MDA or PCA administration are almost entirely of the beaded type and appear to be unaffected by both drugs. Over a wide range of doses (2.5-40 mg/kg PCA) and survival times (2 weeks to 2 months), these spared 5-HT axons with large, spherical varicosities cannot be distinguished from the normal, beaded 5-HT axons in control rats by morphologic criteria. Moreover, beaded 5-HT axons exhibit a highly characteristic regional distribution which is the same in control as in MDA- and PCA-treated rats: these axons innervate specific zones or layers within parietal and occipital cortex, hippocampus, cingulate cortex, entorhinal cortex, and the olfactory bulb, among other forebrain areas, and they form a dense plexus lining the ventricular system. Taken together, the results of this study demonstrate that fine 5-HT axons are highly vulnerable to the neurotoxic effects of the amphetamine derivatives MDA and PCA, while beaded 5-HT axons are markedly resistant. These findings are consistent with the hypothesis that there are two anatomically and functionally distinct sets of serotoninergic neurons projecting to forebrain. While both of these neuronal systems utilize 5-HT as a neurotransmitter, they differ in several features: 1) origin from separate nuclei in the brainstem (the dorsal and median raphe), 2) two types of morphologically distinct axon terminals, 3) markedly different distribution and innervation patterns in forebrain, and 4) dissimilar pharmacological properties. The results further suggest that psychotropic amphetamine derivatives have a selective action upon fine serotoninergic axons that arise from the dorsal raphe nucleus.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1814975     DOI: 10.1002/cne.903140312

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  51 in total

1.  Glucocorticoid receptor deletion from the dorsal raphé nucleus of mice reduces dysphoria-like behavior and impairs hypothalamic-pituitary-adrenocortical axis feedback inhibition.

Authors:  Melanie Y Vincent; Lauren Jacobson
Journal:  Eur J Neurosci       Date:  2014-03-29       Impact factor: 3.386

2.  BDNF promotes the regenerative sprouting, but not survival, of injured serotonergic axons in the adult rat brain.

Authors:  L A Mamounas; C A Altar; M E Blue; D R Kaplan; L Tessarollo; W E Lyons
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

3.  A differentially autoregulated Pet-1 enhancer region is a critical target of the transcriptional cascade that governs serotonin neuron development.

Authors:  Michael M Scott; Katherine C Krueger; Evan S Deneris
Journal:  J Neurosci       Date:  2005-03-09       Impact factor: 6.167

4.  Length of axons expressing the serotonin transporter in orbitofrontal cortex is lower with age in depression.

Authors:  Grazyna Rajkowska; Gouri Mahajan; Beata Legutko; Lavanya Challagundla; Michael Griswold; Paul R Albert; Mireille Daigle; Jose J Miguel-Hidalgo; Mark C Austin; Randy D Blakely; David C Steffens; Craig A Stockmeier
Journal:  Neuroscience       Date:  2017-07-13       Impact factor: 3.590

5.  Chronic administration of 13-cis-retinoic acid does not alter the number of serotoninergic neurons in the mouse raphe nuclei.

Authors:  C J G Drew; K C O'Reilly; M A Lane; S J Bailey
Journal:  Neuroscience       Date:  2010-10-25       Impact factor: 3.590

Review 6.  Modulators in concert for cognition: modulator interactions in the prefrontal cortex.

Authors:  Lisa A Briand; Howard Gritton; William M Howe; Damon A Young; Martin Sarter
Journal:  Prog Neurobiol       Date:  2007-06-30       Impact factor: 11.685

7.  Branch architecture of the fly larval abdominal serotonergic neurons.

Authors:  John Chen; Barry G Condron
Journal:  Dev Biol       Date:  2008-04-09       Impact factor: 3.582

Review 8.  Collateralized dorsal raphe nucleus projections: a mechanism for the integration of diverse functions during stress.

Authors:  Maria Waselus; Rita J Valentino; Elisabeth J Van Bockstaele
Journal:  J Chem Neuroanat       Date:  2011-05-30       Impact factor: 3.052

9.  In vivo [¹⁸F] FDG PET imaging reveals that p-chloroamphetamine neurotoxicity is associated with long-term cortical and hippocampal hypometabolism.

Authors:  Luis García-García; Mercedes Delgado; Ahmed Anis Al-Sayed; Pablo Bascuñana; Rubén Fernández de la Rosa; Paloma Bermejo-Bescós; Sagrario Martín-Aragón; Miguel A Pozo
Journal:  Mol Imaging Biol       Date:  2015-04       Impact factor: 3.488

10.  Glial cell response to 3,4-(+/-)-methylenedioxymethamphetamine and its metabolites.

Authors:  Joseph M Herndon; Aram B Cholanians; Serrine S Lau; Terrence J Monks
Journal:  Toxicol Sci       Date:  2013-12-03       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.